By linear regression analysis adjusted for age and diabetes duration at GLP-1 RA initiation, chronic microvascular complications, and cardiovascular diseases, we explored whether weight at GLP-1 RA initiation was correlated with weight change during therapy. Here, GLP1R is linked to cardiovascular disorder.